US Patent

US8479730 — Inhaler device

Formulation · Assigned to Novartis AG · Expires 2028-10-11 · 2y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an inhaler device for powdered medicaments, specifically designed to hold a capsule and pierce it to release the medicament.

USPTO Abstract

An inhaler device ( 1 ) for powdered medicaments. The device ( 1 ) has a body ( 5 ) that has a recess ( 50 ) for holding a capsule containing a powdered medicament to be inhaled, at least one air passage ( 90 ) that is tangentially disposed to the recess ( 50 ) , and a mouthpiece ( 30 ) that includes a coaxially disposed inhalation passage ( 70 ) that communicates with the recess ( 50 ) of the body ( 5 ). The body ( 5 ) has a pair of opposed spring ( 105 ) biased push-buttons ( 40 ) that each include at least one piercing element ( 95 ) for piercing the capsule when loaded in the recess ( 50 ). The medicament is released from the pierced capsule when air is drawn through the air passage(s) ( 90 ) into the recess ( 50 ) and swirled about therein. The mouthpiece ( 30 ) is pivotally attached to the edge of the body ( 5 ) so that it is pivotable between an open loading position and a closed dispensing position about an axis that is perpendicular to the longitudinal axis of the inhaler ( 1 ).

Drugs covered by this patent

Patent Metadata

Patent number
US8479730
Jurisdiction
US
Classification
Formulation
Expires
2028-10-11
Drug substance claim
No
Drug product claim
Yes
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.